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Purpose: Adrenomedullin (ADM) is a small, secreted peptide often associated with vasodilation. However, ADM can
also function as a neurotransmitter/neuromodulator, and studies suggest ADM is upregulated in the eye in several ocular
diseases. However, no studies to date have described an ADM signaling pathway in the retina.
Methods: PCR, immunocytochemistry, nitric oxide imaging, western blots, and a nitrite assay were used to determine
the localization of the components of the ADM signaling pathway in the mouse retina.
Results: We used reverse-transcriptase polymerase chain reaction to show that ADM and its primary receptor, calcitonin-
receptor-like receptor, along with its associated receptor activity modifying proteins 2 and 3 are expressed in the retina.
Using immunocytochemistry, we detected ADM staining throughout the retina in the photoreceptor outer segments, the
outer nuclear layer, Müller and amacrine cell somata in the inner nuclear layer, and some somata in the ganglion cell layer.
We found that calcitonin-receptor-like receptor and receptor activity modifying protein 2 had localization patterns similar
to ADM, especially in somata in the inner nuclear and ganglion cell layers. Finally, we showed that the ADM receptor
was functional in the retina. Stimulation of isolated retinas with ADM increased cyclic adenosine monophosphate– and
cyclic guanosine monophosphate–like immunoreactivity, as well as nitric oxide production.
Conclusions: These results are the first to show that ADM and functional ADM receptors are present in the retina. Since
ADM is increased in eyes with ocular pathologies such as diabetic retinopathy, glaucoma, retinitis pigmentosa, and uveitis,
the ADM signaling pathway may provide a new target for ameliorating these retinal pathologies.
Adrenomedullin (ADM) is a small, secreted signaling
peptide first identified in a pheochromocytoma of the human
adrenal  gland  and  belongs  to  the  calcitonin  gene–related
peptide family [1]. ADM circulates in the human plasma at
levels  of  2–3  pM  and  is  expressed  in  numerous  organs,
including cardiac muscle and the kidney [1-3]. ADM is also
found throughout the central nervous system (CNS), including
the cerebellum and cerebral cortex [4]. ADM may be involved
in several ocular pathologies. For example, there is increased
ADM in the vitreous humor of patients with diabetes [5,6], in
patients with primary open-angle glaucoma [7], and in the
aqueous  humor  of  patients  with  uveitis  and  vitreoretinal
disorders  [8],  and  patients  with  retinitis  pigmentosa  have
increased plasma ADM [9].
While the earliest discovered activity of ADM was as a
vasodilator [1], ADM also functions as a neurotransmitter/
neuromodulator,  in  that  the  peptide  can  directly  alter  the
electrical responses of neurons in culture [10] and can elicit
calcium transients and activate nitric oxide (NO) production
in  cultured  cortical  neurons  [11].  In  the  eye,  ADM  was
originally found in retinal pigment epithelial (RPE) cells [8,
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12]. Two previous studies have examined ADM in the retina,
but they provide little anatomic detail on the localization of
ADM, and they do not characterize its downstream signaling
or receptors. Zhu et al. [13] performed immunocytochemistry
using an ADM antiserum and reported scattered cells in parts
of the ganglion cell layer (GCL), the inner and outer nuclear
layers (INL and ONL), and the retinal pigment epithelium.
Thiersch et al. [14] found upregulation of the ADM gene in
response to hypoxic preconditioning.
ADM primarily activates the type III G-protein coupled
receptor (GPCR) calcitonin receptor-like receptor (CRLR),
when  CRLR  is  coupled  with  either  the  receptor  activity
modifying  protein  2  or  3  (RAMP2  or  RAMP3)  [15,16].
Binding of ADM to its receptor can lead to an elevation of
cyclic adenosine monophosphate (cAMP) and activation of
protein kinase A (PKA) [1,17]. Xu and Krukoff [11] showed
that  this  activation  of  PKA  can  lead  to  an  increase  in
intracellular calcium, which is consistent with the work of
Kuwasako et al. [18], who also showed intracellular calcium
mobilization via cAMP after ADM binding to CRLR/RAMP.
Other GPCRs have some affinity for ADM. These GPCRs
include the ADM receptor L1 (ADMR-L1) [19] and the RDC1
receptor [20]; however, only CRLR coupled to RAMP2 has
been firmly shown to be specific for ADM [16].
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1339The aim of the current study was to determine whether
ADM and a functional ADM receptor are present in the mouse
retina. We immunocytochemically localized the expression of
ADM and/or its receptors in the outer plexiform layer (OPL),
inner plexiform layer (IPL), and in somata in the GCL, the
INL, and the ONL. We confirmed the expression of ADM,
CRLR,  RAMP2,  and  RAMP3  in  the  retina  using  reverse-
transcriptase polymerase chain reaction (RT–PCR), and the
presence of a functional ADM receptor by stimulating with
ADM  and  showing  an  increase  in  cAMP-like
immunoreactivity  (LI),  cyclic  guanosine  monophosphate
(cGMP)-LI, and NO production. The results of our study
indicate the existence of a functional ADM signaling cascade
in neurons of the mouse retina.
METHODS
Unless specified otherwise, all reagents were purchased from
Sigma (St. Louis, MO) or ThermoFisher Scientific (Waltham,
MA). All images were labeled, arranged, and prepared for
display using Corel Draw (Corel Corp., Ottawa, ON) unless
otherwise noted.
Animals:  Adult,  male  C57BL/6  mice  were  purchased
from Charles River Laboratories (Wilmington, MA) and were
kept on 12 h:12 h light-dark cycles with free access to food
and water. All animals were treated using protocols approved
by the Boston University Charles River Campus Institutional
Animal Care and Use Committee (IACUC).
Immunocytochemistry:  Animals  were  first  heavily
anesthetized using 3.0% IsoFlo isoflurane gas via a general
anesthesia apparatus (Abbott Laboratories, North Chicago,
IL) and then decapitated. The eyes were then enucleated and
the anterior chambers immediately removed in ice-cold rodent
balanced salt solution (BSS; 137 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 15 mM D-glucose, 1 mM MgSO4, 1 mM Na2HPO4,
10 mM HEPES, pH 7.4) and then placed directly into 4%
paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4 for
60 min. The eyecups were then cryoprotected in 30% sucrose
in PB, embedded and frozen in optimal cutting temperature
(OCT) embedding media (Tissue-Tek, Miles, Inc., Elkhard,
IN) cut into 14-µm-thick cross sections using a cryostat, and
then  collected  on  SuperFrost/Plus  slides  (ThermoFisher
Scientific).  Immunochemistry  (ICC)  was  performed  using
previously described conventional methods [21]. Sections on
slides were washed with 0.1 M PB to remove excess OCT. All
antiserum solutions were diluted in 0.1 M PB with 0.3% Triton
X-100  (PBtx).  Non-specific  labeling  was  blocked  by
incubation  in  5%  normal  goat,  donkey,  or  rabbit  serum
(Jackson  ImmunoResearch  Labs,  West  Grove,  PA)  as
appropriate, in PBtx for 1 h. Cross sections were incubated in
primary  antiserum  overnight  (Table  1).  Following  the
incubation in primary antiserum, the sections were washed in
PB and incubated for 2 h in fluorescent secondary antisera as
appropriate. The secondary antisera used were an Alexa Fluor
488-conjugated  donkey  antigoat,  donkey  antirabbit,  or
donkey  antimouse  immunoglobulin  G  (IgG;  Invitrogen,
Grand  Island,  New  York)  and  a  CY3-conjugated  donkey
antigoat IgG (Jackson ImmunoResearch Laboratories, Inc.
West  Grove,  PA)  used  at  a  dilution  of  1:500  in  PBTX.
Incubation  with  only  secondary  antiserum  was  used  as  a
control  for  non-specific  secondary  antiserum  staining.  To
control  for  specificity,  the  ADM  antisera  (sc-16496)  was
incubated overnight with the synthetic peptide the antisera
was raised against (ADM C-20 P sc-16496) before it was
incubated  with  the  cross  sections.  For  double-labeling
experiments,  each  secondary  antiserum  was  excited  by  a
separate laser (488 nm or 568 nm) and recorded in a separate
channel.  Images  used  for  colocalization  analysis  were
captured separately. The accuracy of the double labeling was
confirmed by analyzing the labeling in single optical sections,
while the specificity of the double labeling was confirmed by
testing a given primary antisera with the opposite secondary
antisera.
Finally, the slides were washed in PB and coverslipped
with glycerol, and the fluorescent labeling was visualized
using  an  Olympus  Fluoview  300  confocal  microscope
(Olympus, Melville, NY). Image J image analysis software
TABLE 1. LIST OF ANTISERA USED
Antigen Antiserum Source [catalog number],[reference number] Working dilution
ADM Goat anti-ADM Santa Cruz Biotechnology [sc-16496] 1:50
ADM Rabbit anti-ADM Santa Cruz Biotechnology [sc-33187] 1:100
CRLR Rabbit anti-CRLR GeneTex [GTX100340] 1:250
RAMP2 Rabbit anti-RAMP2 GeneTex [GTX108524] 1:250
Glutamine synthetase Rabbit anti- glutamine synthetase Sigma Aldrich [G2781] [45] 1:100
PKCα Mouse anti- PKCα Transduction Laboratories [610107] [45] 1:1,000
Calbindin Mouse anti-calbindin-D28K Sigma Aldrich [C94848] [45] 1:1,000
Calretinin Rabbit anti-Calretinin Millipore [MAB1568] [45] 1:1,000
nNOS Rabbit anti-nNOS Santa Cruz Biotechnology [sc-648] [22] 1:100
Glutamate Rabbit anti-glutamate Dr. David Pow [50] 1:100
GABA Rabbit anti-GABA Dr. David Pow [50] 1:100
Glycine Rabbit anti-glycine Dr. David Pow [50] 1:100
cAMP Rabbit anti-cAMP Calbiochem EMD Pharmaceuticals [116820] [51] 1:1,2500
cGMP Rabbit anti-cGMP Dr. Jan de Vente [52] 1:10,000
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1340(Wayne  Rasband,  National  Institute  of  Mental  Health,
Bethesda, MD) was used to convert images to inverted gray
scale such that the immunoreactivity appeared black. The z
project function of Image J was used to obtain a single image
from a collapsed confocal optical stack.
RNA  isolation,  reverse  transcription,  and  reverse-
transcriptase polymerase chain reaction: All animals were
first anesthetized using isoflurane gas and then decapitated as
described  above.  Following  decapitation,  the  retinas  were
surgically  isolated  in  RNase-free  rodent  BSS  and  placed
immediately in 1.5 ml microcentrifuge tubes on dry ice. Six
retinas  (three  animals)  were  typically  pooled  together  to
ensure an adequate amount of RNA. Total RNA was then
isolated  using  a  standard  TRIzol  reagent  (Invitrogen,
Carlsbad,  CA)  extraction  followed  by  further  purification
using  Qiagen’s  RNeasy  Kit  (Qiagen,  Valencia,  CA)  with
modifications as described previously by Giove et al. [22].
Three  hundred  ﬁfty  microliters  of  buffer  RLT  with  β-
mercaptoethanol was added per 100 µl of RNA. Two hundred
ﬁfty microliters of 100% ethanol was then added, and the
solution was mixed thoroughly before being placed into the
provided RNeasy spin columns. The solution was centrifuged
for 15 s at 10,000× g and the ﬂow-through discarded. The
column was then washed twice with 500 µl of buffer RPE and
centrifuged for an additional 1 min to remove residual liquid.
The column was then transferred to a clean 1.5-ml centrifuge
tube,  and  elution  was  performed  per  the  manufacturer’s
instructions.  The  RNA  was  then  treated  with  rDNase
(Ambion, Applied Biosystems) based on the manufacturer’s
instructions to remove any DNA contaminants. The RNA was
quantified  using  a  NanoDrop  spectrophotometer
(ThermoFisher Scientific). cDNA was then made using the
Verso cDNA Kit (ThermoFisher Scientific) and subsequently
treated with 2 U of RNase H (ThermoFisher Scientific) at
37 °C for 20 min.
PCR was performed to amplify mouse CRLR, RAMP2,
RAMP3, and ADM using the primers and conditions outlined
in Uzan et al. [23] with 4 µl of cDNA converted from 1 µg of
retinal  RNA.  The  cDNA  was  amplified  with  Taq  DNA
polymerase and specific primers as indicated in Table 2. Ten
µl of each reaction was then run on an ethidium bromide
stained 1.2% agarose gel and imaged on Gel Doc XR (Bio-
Rad, Hercules, CA) with its associated Quantity One software
(Bio-Rad).  Gel  images  were  inverted  for  display.  PCR
products  were  confirmed  by  using  automated  DNA
sequencing (SeqWright, Houston, TX).
In vitro stimulation with adrenomedullin: Following the
dissections described above, the isolated retinas were allowed
to recover for 45 min at room temperature in Ames culture
media. Isolated retinas were then preincubated for 20 min at
room  temperature  in  aerated  BSS  with  the  nonspecific
phosphodiesterase  (PDE)  inhibitor  3-isobutyl-1-
methylxanthine (1 mM). Following the preincubation with
inhibitor  3-isobutyl-1-methylxanthine,  the  full-length  rat
ADM peptide (200 nM; American Peptide, Sunnyvale, CA)
was added to the Ames media. This concentration was chosen
based on an electrophysiological study of the effects of bath-
applied  ADM  on  rat  brain  slices  that  indicated  this
concentration  produced  clear  electrophysiological  effects
[10]. After 1 h of stimulation at 37 °C with 95%O2/5%CO2,
the isolated retinas were fixed for 2 h and then prepared for
immunocytochemical analysis as described previously.
Western blot analysis: Retinas from enucleated eyecups
were removed and homogenized with ultrasonification in lysis
buffer (50 mM Tris-HCl pH 7.5, 250 mM sucrose, 1 mM
EDTA,  1%  NP-40,  0.1%  sodium  dodecyl  sulfate,  0.5%
deoxycholate acid, 10 mM L-phenylmethylsulfonyl fluoride,
1% protease and phosphatase inhibitor cocktail [Halt; Thermo
Scientific, Rockford, IL]). Retinal homogenates were spun
down at 500× g for 5 min, and the resultant supernatants were
used for analysis. Protein concentrations were determined
with a modified Bradford assay. Forty micrograms of protein
per  lane  were  electrophoresed  on  4%–20%  Tris-glycine
Pierce Protein precast gels (Thermo Scientific, Rockford, IL)
at 150 V for 90 min and then were transferred for 2 h (80 V)
to a polyvinylidene fluoride (PVDF) membrane (Millipore
Corporation,  Billerica,  MA).  Following  washes  in  Tris-
buffered saline with Tween-20 (TBST: 50 mM Tris, 150 mM
sodium  chloride,  1  mM  magnesium  chloride,  and  0.25%
Tween-20, pH 7.4), the membranes were blocked with 5%
dried  milk  in  TBST  for  1.5  h  at  room  temperature  and
TABLE 2. PRIMER SEQUENCES USED.
Gene Primer Sequences (5′-3′) PCR product (bp) Annealing temp (°C)
ADM F: CGAAAGAAGTGGAATAAGTGGG 200 60
  R: GTTCATGCTCTGGCGGTAGCG    
CRLR F: GCTGAATGACGTTGCAGC 480 60
  R: GCCTTCACAGAGCATCCA    
RAMP2 F: CATGGACTCTGTCAAGGACTG 153 55
  R: GTGTATCAGGTGAGCCT    
RAMP3 F: ACCTGTCGGAGTTCATCG 262 55
  R: ATCAGTGTGCTTGCTGCG    
          Primer sequences used in this study for RT–PCR (ADM, CRLR, RAMP2, RAMP3).
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1341incubated in primary antiserum diluted in 3% milk in TBST
for  2  h.  After  the  membranes  were  washed  in  TBST,  an
antirabbit  IgG  secondary  antiserum  conjugated  to  CY5
(1:1,000;  Jackson  ImmunoResearch)  was  applied  for  1  h.
After the membranes were washed several times in TBST,
fluorescence was detected using a Typhoon Variable Mode
Imager (GE Healthcare, Piscataway, NJ). Molecular weight
determinations  were  done  using  Multi-Analyst  (Bio-Rad)
software.
Nitrite analysis: Isolated mouse retinas were first allowed
to  recover  for  30  min  in  Ames  media.  They  were  then
incubated for 30 min with or without 1 mM of the nitric oxide
synthase (NOS) inhibitor L-nitro-arginine methyl ester (L-
NAME),  followed  by  stimulation  with  ADM  (200  nM;
American Peptide) for 30 min. The use of the NOS inhibitor
allowed us to confirm that the increased nitrite was due to the
synthesis of NO and its decomposition to nitrite. The culture
medium was then collected and used for nitrite analysis, and
the retina was homogenized to determine total protein levels
using a modified Bradford assay. Nitrite analysis was done
using a modified Griess reaction using vanadium(III) chloride
to convert nitrate to nitrite [24]. Nitrite levels were normalized
to total protein levels, and the results were analyzed using a
two-way ANOVA (n=6).
RESULTS
Adrenomedullin  was  expressed  in  the  mouse  retina:  We
confirmed the expression of ADM in the retina using RT–PCR
(Figure 1A). ADM-LI was detected weakly throughout the
retina but was strongly localized near the photoreceptor outer
segments, in elongated somata in the middle of the INL, and
in some large somata in the GCL (Figure 2A) compared to an
absorption control (Figure 2B) and a no primary control (not
shown). We also observed faint ADM-LI in the cytoplasm of
somata in the INL adjacent to the IPL.
Although we did not confirm the specificity of either of
the ADM antisera using western blots, we established the
immunocytochemical specificity of the antisera because each
ADM antiserum was directed against a different epitope on
ADM. The one antiserum from Santa Cruz (Santa Cruz, CA,
sc-16496) was directed against an epitope mapping within an
internal region of ADM, while the other antiserum (sc-33187)
was directed against an epitope corresponding to amino acids
1–185  representing  full-length  ADM  of  human  origin.
Although both antisera showed qualitatively similar labeling
that indicated the specificity of the labeling, we show only the
labeling with the sc-16496 antiserum as it was more robust.
Additionally, we show no staining in control tissue when
ADM was preabsorbed with the synthetic peptide (Figure 2B).
Using an ADM knockout mouse to test for AM antibody
specificity  was  not  possible  as  homozygous  AM  (AM−/−)
knockout  mice  die  in  utero  around  mid-gestation  from
systemic hemorrhage and edema resulting from the fragility
of their vasculature [25].
Although there was some faint ADM-LI in the outer
nuclear layer, it does not seem likely that the strong punctate
ADM-LI near the photoreceptor outer segments is actually in
the outer segments themselves. Given that ADM has been
previously localized in the RPE [8,12], it is more probable that
the punctate ADM-LI is either from ADM secreted by the
RPE,  from  broken  RPE  cell  fragments  sticking  to  the
photoreceptor  outer  segments,  or  from  RPE  processes
interdigitating with the outer segments.
To accurately identify the specific cell types that were
positive for ADM-LI, cross sections were double-labeled with
ADM antiserum and cell specific markers. Colocalization of
ADM-LI with the Müller cell marker glutamine synthetase
Figure  1.  Adrenomedullin  (ADM),
calcitonin  receptor  like  receptor
(CRLR), and eceptor activity modifying
protein  (RAMPs)  needed  for  ADM
signaling are expressed in the retina. A:
Reverse transcriptase (RT)–PCR using
ADM specific primers [23] showed a
single  band  at  the  expected  size  of
approximately  225  bp.  Lane  1=ADM
RT–PCR; Lane 2=no template control;
Lane  3=NEB  50  bp  ladder  (New
England  BioLabs,  Ipswich,  MA),
darkest band=200 bp. B: RT–PCR using
primers described by Uzan et al. [23]
confirmed  the  expression  of  CRLR
(Lane  1,  approximately  700  bp),
RAMP3  (Lane  2,  approximately  250
bp),  and  RAMP2  (Lane  3,
approximately  190  bp).  Lane  4=NEB
100 bp ladder.
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1342Figure 2. Adrenomedullin (ADM) in the mouse retina. A: ADM-like immunoreactivity (LI) was predominantly localized in cell somata in the
middle layer of the inner nuclear layer (INL; horizontal arrow), and in presumptive ganglion cell somata in the ganglion cell layer (GCL;
down arrow), and near the outer segments (OS; diagonal arrow). We also observed faint ADM-LI in the cytoplasm of somata in the INL
adjacent to the inner plexiform layer (IPL; up vertical arrow). B: There was no labeling in control sections in which the ADM primary antiserum
was preincubated with the peptide the antiserum was raised against. Inner segments=IS, Scale bars=20 μm.
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1343Figure 3. Colocalization of adrenomedullin (ADM) with cell specific markers was done to accurately identify cell types with ADM-like
immunoreactivity (LI). In all figures, ADM-LI was localized near the photoreceptor outer segments and in somata in the inner nuclear layer
(INL) and the ganglion cell layer (GCL). A: Glutamine synthetase (GS, red) labeled Müller cells, and colocalized with ADM (green) in their
somata in the INL (horizontal arrow). B: Protein kinase C α-like immunoreactivity (PKCα-LI; green) was present in rod bipolar cells and did
not colocalize with ADM-LI (red). C: Calbindin-LI (green) was localized in horizontal cells in the INL and their process in the OPL, as well
as in somata in the INL and GCL. ADM-LI (red) colocalized with calbindin-LI in somata in the lower tier of the INL that borders the IPL
(vertical arrow) and in somata in the GCL (diagonal arrow). D: Calretinin-LI (green) was localized in amacrine cell somata in the INL, in
processes in the inner plexiform layer (IPL), and within somata in the GCL. ADM-LI (red) did not colocalize with calretinin-LI. E: neuronal
nitric oxide synthase (nNOS)-LI (green) was localized in select amacrine cell somata in the INL, in processes in the IPL, and in somata in the
GCL. Some somata with nNOS-LI in the GCL colocalized with ADM-LI (red) (arrow). F: Glutamate-LI (red) was localized near the
photoreceptor outer segments, in the OPL, in somata in the INL and the GCL, and as diffuse staining in the IPL. ADM-LI (green) colocalized
with glutamate near the outer segments (arrow). G: Glycine-LI (red) was localized in the INL, in the OPL and the IPL, and in somata in the
INL and the GCL. Glycine-LI was not colocalized with ADM-LI (green) in any somata, but there was some potential colocalization in puncta
in the IPL (arrow). H: gamma-aminobutric acid (GABA)-LI (red) was localized to somata in the ONL, processes in the OPL, somata in the
INL, diffusely in the IPL, and somata in the GCL. ADM-LI (green) did not colocalize with GABA-LI. Scale bars=20 µm.
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1344(Figure 3A) demonstrated that the ADM-LI positive somata
in the middle of the INL were Müller cells. The other cell
somata in the middle of the INL were not rod bipolar cells as
there was no colocalization of ADM-LI with the rod bipolar
cell  marker  protein  kinase  Cα  (Figure  3B).  Additionally,
ADM-LI was not localized in horizontal cells as demonstrated
by the horizontal cell marker calbindin (Figure 3C). Although
ADM-LI was not in horizontal cells, it was colocalized with
calbindin-LI in somata in the INL on the border with the IPL,
and within somata in the GCL, supporting that ADM-LI is in
amacrine cells and either displaced amacrine or ganglion cells.
ADM-LI positive cells did not colocalize with amacrine cells
that were positive for calretinin-LI (Figure 3D) or neuronal
nitric oxide synthase (nNOS)-LI (Figure 3E). However, some
somata with nNOS-LI in the GCL did colocalize with ADM-
LI.  ADM-LI  was  colocalized  with  the  excitatory
neurotransmitter  glutamate  in  the  photoreceptor  outer
segments (Figure 3F), but not within the rest of the retina.
ADM-LI  did  not  colocalize  with  the  inhibitory
neurotransmitters  glycine  (Figure  3G)  or  gamma-
aminobutyric acid (Figure 3H) in amacrine cell somata, but
there  was  some  potential  colocalization  of  glycine  in
occasional puncta in the IPL.
Adrenomedullin receptors were present in the mouse retina:
We used RT–PCR to determine whether the primary ADM
receptor, CRLR, and its associated receptor activity modifying
proteins  were  expressed  in  the  retina.  We  detected  the
expression of CRLR, RAMP2, and RAMP3 (Figure 1B). We
then  used  immunocytochemistry  to  localize  the  ADM
receptors in the retina. Because we were unable to find a
reliable antiserum against RAMP3, we focused on CRLR and
RAMP2. CRLR-LI was detected primarily in large somata in
the GCL, in faint puncta in the OPL, in photoreceptor outer
segments or the RPE, in photoreceptor inner segments, and in
Figure  4.  Immunocytochemical
localization  of  the  adrenomedullin
(ADM) receptor calcitonin receptor like
receptor (CRLR) and receptor activity
modifying  protein  (RAMP2).  A:  The
ADM  receptor  CRLR-like
immunoreactivity  (LI)  was  localized
near  the  outer  segments  of
photoreceptors  (diagonal  arrow),  in
faint somata in the outer nuclear layer
(ONL; horizontal arrow), in puncta in
the  outer  plexiform  layer  (OPL;
asterisk),  in  select  cell  somata  in  the
inner nuclear layer (INL; arrowhead), in
delicate puncta in the inner plexiform
layer (IPL), and in numerous somata in
the ganglion cell layer (GCL; vertical
arrow).  B:  RAMP2-LI  was  localized
near the photoreceptor outer segments
(diagonal arrow), in somata in the ONL
(horizontal arrow), and in somata in the
INL  (arrowhead)  and  GCL  (vertical
arrow). Scale bars=20 µm. C: western
blot  of  mouse  retinal  homogenate
probed  with  the  same  CRLR  and
RAMP2  antisera  used  for
immunocytochemistry.  Both  antisera
recognized  single  proteins  with  the
correct molecular weights.
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1345Figure 5. Colocalization of adrenomedullin (ADM) with its receptor. A: ADM-like immunoreactivity (LI; red) was colocalized with calcitonin
receptor like receptor (CRLR; green) in somata in the inner nuclear layer (INL; diagonal arrow) and somata in the ganglion cell layer (GCL;
down arrow). B: ADM-LI (green) was colocalized with RAMP2 near the outer segments (up arrow), in cell somata in the ONL (horizontal
arrow), and in somata in the INL (diagonal arrow) and the GCL (down arrow). Scale bars=20 µm.
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1346the cytoplasm of numerous faint somata in the ONL and the
INL (Figures 4A and Figure 5A). We found RAMP2-LI was
strongly localized in many somata in the INL and the GCL,
in faint somata in the outer ONL, and in photoreceptor outer
segments (Figure 4B). The RAMP2-LI in the INL was present
in numerous somata that resembled amacrine cells by location
and morphology. The specificity of the CRLR and RAMP2
antisera was confirmed using western blots that recognized
proteins of the correct molecular weight (Figure 4C). Labeling
in CRLR or RAMP2 knockout mice as a control for specificity
was not possible as CRLR (CRLR−/−) and RAMP2 (RAMP2−/
−)  knockout  mice  are  embryonic  lethal  due  to  vascular
complications [26,27].
To  determine  if  ADM-LI  and  its  receptors  were
colocalized, cross sections were double-labeled with ADM
antisera and either CRLR or RAMP2 antisera. ADM-LI was
colocalized with CRLR in somata in the INL and the GCL but
was not colocalized in the outer segments or the OPL (Figure
5A).  ADM-LI  was  colocalized  with  RAMP2  in  the  outer
segments, in somata in the ONL, as well as in some somata in
the INL and the GCL (Figure 5B).
Adrenomedullin  receptors  were  functional  in  the  mouse
retina:
Adrenomedullin  simulates  production  of  cyclic
adenosine  monophosphate  and  cyclic  guanosine
monophosphate—Isolated  retinas  were  stimulated  with
ADM (200 nM), and immunocytochemistry was then used to
detect the downstream second messengers cAMP and cGMP
(Figure 6). We found an increase in cAMP-LI and cGMP-LI
when isolated retinas were stimulated with ADM.
In the control retinas, faint cAMP-LI was localized in rare
somata in the ONL, faint labeling in the OPL, sparse somata
in the INL, isolated puncta in the IPL, and in some faint somata
in the GCL (Figure 6A). There was an overall increase in
cAMP-LI when retinas were stimulated with ADM. We found
a  large  increase  in  the  number  of  photoreceptor  somata,
increased staining in the OPL and the IPL, and many more
strongly labeled somata in the INL and the GCL (Figure 6B).
Increased cAMP-LI in axons in the ganglion cell axon layer
supported that at least some of the labeled somata in the GCL
were ganglion cells.
Faint  cGMP-LI  was  localized  in  photoreceptor  outer
segments and in somata in the outer retina in the control retinas
Figure  6.  Stimulation  with  200  nM
adrenomedullin (ADM) increases cyclic
adenosine monophosphate (cAMP)-like
immunoreactivity  (LI)  and  cyclic
guanosine monophosphate (cGMP)-LI.
A: In the control retinas, cAMP-LI was
in isolated somata in the outer nuclear
layer (ONL; horizontal arrow), in faint
staining  in  the  outer  plexiform  layer
(OPL; asterisk), in sparse somata in the
inner  nuclear  layer  (INL;  diagonal
arrow), in diffuse puncta in the inner
plexiform layer (IPL), and in somata in
the  ganglion  cell  layer  (GCL;  down
arrow).  B:  In  retinas  stimulated  with
ADM, there was an overall increase in
cAMP-LI,  with  increased  numbers  of
photoreceptor  somata  (horizontal
arrow), puncta in the OPL (asterisk), and
somata in the INL (diagonal arrow) and
the GCL (down arrow). C: In the control
retinas,  faint  cGMP-LI  was  in  some
photoreceptor outer segments (vertical
arrow)  and  in  somata  in  the  inner
(diagonal arrow) and outer (horizontal
arrow) ONL. D: In retinas stimulated
with ADM, there was an increase in the
number  and  intensity  of  labeled
photoreceptor  outer  segments  (up
arrow) and somata in the inner region of
the ONL (diagonal arrow). There were
also  some  faint  somata  in  the  INL
(horizontal arrow). Scale bars=20 µm.
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1347(Figure 6C). There was a dramatic increase in the number and
intensity of labeled photoreceptor outer segments and somata
in retinas stimulated with ADM (Figure 6D). There were also
some faint somata in the INL.
Adrenomedullin stimulates an increase in nitric oxide
degradation  products—Nitrite  analysis  was  used  as  a
measure of NO production in isolated retinas stimulated with
ADM. There was a statistically significant increase (p<0.001)
in NO production in retinas that were stimulated with ADM
(200 nM), and a statistically significant decrease (p<0.001) in
NO production when the isolated retinas were stimulated with
ADM in the presence of the NOS inhibitor L-NAME (1 mM;
Figure 7). The decrease in nitrite to below control levels seen
with L-NAME indicated that basal levels of NOS activity
were inhibited as well.
DISCUSSION
Presence of a functional adrenomedullin signaling pathway
in  the  retina:  Although  ADM  was  first  described  as  a
vasodilator [1], it has become clear that ADM has many other
diverse functions, including neurotransmission [4,28]. Our
anatomic localization confirms and adds detail to the previous
localization of ADM in the mouse retina [13]. We detected
ADM in several neural layers of the mouse retina, with the
strongest expression in Müller cell somata in the INL and
displaced amacrine and/or ganglion cell somata in the GCL,
and more diffusely in amacrine cell somata in the INL. The
localization of the ADM positive somata in the middle of the
INL and the close numerical correlation of the somata with
ADM to the number of Müller cell processes strongly suggest
that these somata are from Müller cells. Moreover, detailed
anatomic studies of mouse bipolar cells indicate that most
bipolar  cell  somata  are  located  more  closely  to  the  outer
plexiform  layer  and  not  in  the  middle  of  the  INL  [29].
However, some of the somata in the INL could be bipolar
cells.
Most importantly, we found that the primary receptor for
ADM,  CRLR,  and  its  associated  RAMP2  had  largely
overlapping expression with ADM, especially in Müller cell
somata and in presumptive ganglion cell somata in the GCL.
The increased levels of cAMP-LI, cGMP-LI, and nitrite in
response  to  stimulation  with  the  ADM  peptide  provided
further evidence of a functional ADM receptor and an ADM/
NO signaling pathway in the mouse retina (Figure 8).
ADM production can be regulated in several ways. The
ADM gene has been shown to have cAMP and protein kinase
C enhancer elements [30], and protein kinase C and cAMP are
involved in many aspects of retinal function. In this report, we
provide  evidence  that  ADM  stimulation  can  increase
production of the NO degradation product nitrite. We have
previously shown that every cell type in the retina can make
NO [31]. Interestingly, NO itself has been shown to stimulate
adrenomedullin  secretion  and  gene  expression  [32].
Therefore, the production and secretion of ADM in the retina
can theoretically be regulated by every cell type in the retina.
Adrenomedullin receptors in the retina: ADM is a secreted
peptide that can function in an autocrine or paracrine manner,
as  seen  in  rodent  development  [33].  In  addition,  ADM
normally circulates in the bloodstream [34], and ADM can
cross the blood–brain barrier (BBB) [35]. Since the BBB and
the blood–retinal barrier (BRB) are similar, this raises the
possibility that the retina can respond to circulating levels of
ADM  in  addition  to  locally  secreted  ADM.  Conversely,
ADM’s ability to cross the BRB may account for the increased
plasma  levels  of  ADM  seen  in  patients  with  retinitis
pigmentosa [9].
Although the CRLR/RAMP2 receptor complex would
clearly  be  functional  when  it  is  inserted  into  the  cell
membrane, there can also be unique intracellular punctate
localization of RAMP2 (Figure 9). The binding of agonists
often leads to the rapid internalization of many cell surface G-
protein coupled receptors, including adrenomedullin binding
to CRLR/RAMP2 receptors [18]. This internalized receptor
is then incorporated into endosomes and then degraded. The
Figure  7.  Stimulation  with
adrenomedullin (ADM) increases nitric
oxide  (NO)  production.  In  isolated
retinas stimulated with ADM (200 nM),
there  was  a  statistically  significant
increase in nitrite (i.e., NO) production.
There  was  a  statistically  significant
decrease in nitrite production when the
isolated  retinas  were  stimulated  with
ADM  in  the  presence  of  the  nNOS
inhibitor  Nω-Nitro-L-arginine  methyl
ester  (L-NAME).  Asterisks  denote
p<0.001 (two way ANOVA n=6; error
bars represent the standard deviation).
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1348Figure 8. Summary diagram of the proposed adrenomedullin (ADM) signaling pathway in the retina. Protein kinase C (PKC) activation can
lead to increased transcription of the ADM gene via a PKC enhancer element. The ADM precursor preproadrenomedullin is cleaved to
proadrenomedullin, which is then cleaved into the secreted peptide ADM and the proadrenomedullin NH2-terminal peptide (PAMP). ADM
is secreted and binds to the G-protein coupled receptor calcitonin receptor like receptor (CRLR) that is associated with either the receptor
activity modifying protein RAMP2 or RAMP3 to activate a signaling cascade that increases cyclic adenosine monophosphate (cAMP) by
activating adenylyl cyclase. Increases in cAMP levels activate protein kinase A (PKA), which increases calcium levels by opening membrane
calcium channels or by releasing intracellular calcium stores. The overall increase in intracellular calcium can increase nitric oxide (NO)
production by directly stimulating nNOS or by activating nNOS through the activation of the calcium-activated phosphatase, calcineurin
(CaN), which dephosphorylates nNOS at an inhibitory phosphorylation site at serine847. Increases in NO production can then increase in cGMP
synthesis by activating soluble guanylyl cyclase (sGC).
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1349punctate  labeling  we  see  might  represent  RAMP2  within
endosomes.
The strong expression of ADM, CRLR, and increased
cAMP-LI in response to ADM in somata in the GCL cells
suggests that ADM functions in an autocrine manner in the
retina as well. However, the localization of ADM-stimulated
increases in cAMP-LI and cGMP-LI in the ONL and cGMP-
LI in photoreceptor outer segments suggests that ADM can
also function in a paracrine fashion in the retina. Given our
localization of CRLR-LI and RAMP2-LI in the outer retina,
ADM  coming  from  the  pigment  epithelium  [8]  could
influence these receptors in the outer retina in a paracrine
fashion.
Additional potential ADM receptors, ADMR-L1 [19],
RDC1 [20], and hrhAM [36], were not investigated in our
study. However, the results of studies examining the affinity
of ADM for these other receptors are inconsistent, suggesting
that the only truly specific ADM receptor is CRLR [16] when
it is associated with RAMP2. In fact, CRLR has complete
specificity for ADM only when CRLR is associated with
RAMP2, because when CRLR is associated with RAMP3,
CRLR can bind to either ADM or the related peptide amylin
[37].  Although  there  are  no  published  studies  localizing
amylin in the retina, like ADM, amylin can cross the BBB
[38], suggesting that amylin could still exert an effect on the
retina  if  the  CRLR/RAMP3  combination  is  present  and
activated.
Adrenomedullin  activation  of  downstream  signaling:
Although  ADM  has  been  implicated  in  several  ocular
diseases, it is important to consider what role ADM may play
in normal retinal function. Many studies have focused on the
diverse roles of NO in the function of retinal neurons [39]. NO
can have many neurochemical effects on retinal neurons, such
as modulating gamma-aminobutyric acid and glycine release
[40], influencing cholinergic signaling [41], and modulation
of gap junctional conductance between horizontal cells [42]
and between AII amacrine cells and cone bipolar cells [43].
Xu and Krukoff [11] have reported that ADM can increase
NO production in cortical neurons through the activation of
the  calcium-activated  phosphatase,  calcineurin,  which
dephosphorylates  neuronal  NOS  (nNOS)  at  an  inhibitory
phosphorylation site at serine847. Previous studies show that
the  expression  of  calcineurin  [44]  and  nNOS  [22,45]  can
overlap in the GCL, IPL, INL, and OPL, which is where we
found ADM and its receptors. Therefore, the ADM signaling
pathway  might  modulate  NO  production  in  normal  and
pathological retinas. For example, increases in retinal ADM
may  increase  retinal  NO  through  a  dephosphorylation  of
nNOS as described by Xu and Krukoff [11].
The fact that CRLR and RAMP2 are located in many
somata  in  the  inner  retina  while  stimulation  with  ADM
primarily increases cAMP-LI and cGMP-LI in the outer retina
indicates that activation of CRLR may also activate other
signaling pathways in the inner retina. For instance, in the rat
Figure 9. Summary of the cellular localization of the ADM signaling
pathway in the retina. ADM was present near the outer segments
(OS), in somata in the INL and the GCL, and in Müller cells. CRLR
and RAMP2 were present near the OS, and in somata in the ONL,
INL, and GCL. ADM, CRLR, and RAMP2 were colocalized near
the OS, and in somata in the INL and the GCL.
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1350heart  ADM  mobilizes  Ca2+  release  from  intracellular
ryanodine- and thapsigargin-sensitive Ca2+ stores, increases
Ca2+  influx  through  L-type  Ca2+  channels,  and  activates
protein kinase C [46]. In vascular endothelial cells, ADM can
transactivate  the  tyrosine  kinase  domain  of  the  vascular
endothelial  growth  factor  receptor  2  [47].  Finally,
intracerebroventricular administration of ADM increases the
expression of c-fos in neurons in rat cardiovascular-related
brain nuclei [48]. The more extensive localization of RAMP2-
LI  compared  to  CRLR-LI  may  be  a  reflection  of  the
association  of  RAMP-2  with  other  G-protein  coupled
receptors in addition to CRLR [49]. Future studies should
analyze the presence of additional ADM receptors, such as
RDC1, and ADMR-L1, although they are not optimal ADM
receptors. It will also be important to determine whether there
are  changes  in  ADM  expression  or  in  the  activity  of  its
downstream signaling components in pathologies known to
increase ADM levels such as diabetic retinopathy, glaucoma,
retinitis pigmentosa, or uveitis. A better understanding of the
activation or inhibition of the system will also provide insight
into the role ADM plays in normal retinal synaptic processing.
Given the widespread localization of ADM and its receptors
in the retina, ADM and its signaling pathways may prove to
be important mediators of retinal function and may provide
valuable new targets for ameliorating retinal pathology.
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